Navigation Links
Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
Date:6/28/2010

Table 98: GERD Therapeutics Market, Global, Usage Patterns, 2009-2016 77

Table 99: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2001-2009 81

Table 100: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2009-2016 81

Table 101:Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 82

Table 102:Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 82

Table 103: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2001-2009 83

Table 104: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2009-2016 83

Table 105: Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 85

Table 106:Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 85

Table 107:Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2001-2009 86

Table 108:Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2009-2016 86

Table 109:Crohn's Disease Therapeutics Market, Global, Prescription Population, 2001-2009 87

Table 110:Crohn's Disease Therapeutics Market, Global, Prescription Population, 2009-2016 87

Table 111:Crohn's Disease Therapeutics Market, Global, Usage Patterns, 2001-2009 89

Table 112:Crohn's Disease Therapeutics Market, Global, Usage Patterns, 2009-2016 89

Table 113: Gastrointestinal Disorder Therapeutics Market, Global, Market Drivers, 2009 92'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
(Date:6/18/2013)... June 18, 2013 Mapi Pharma Ltd. ... and innovative intermediates, and finished dosage forms based on selected ... granted a United States patent for ... Europe for the oral treatment of moderate-to-severe acute ... Intermediate Compounds and Processes for the Preparation of Tapentadol ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that Allergan, Inc.,(NYSE: ... States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s acquisition of ...
... announced that it has filed a registration statement on Form,S-1 ... proposed,initial public offering of its common stock. All of ... The,number of shares to be offered and the price range ... to apply to have its common stock,approved for quotation on ...
... 19 ,Arpida Ltd (SWX: ARPN) was invited to ... new antimicrobial agents at the 47th annual,Interscience Conference ... is a major scientific conference where thousands of,scientists ... to discuss the,latest developments in the field of ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
(Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... 15, 2011 BGI, the world,s largest genomics organization, ... Oregon State University to conduct collaborative de novo genome ... plant pathogens. This agreement kicks off a larger ... Genus Sequencing Consortium, to conduct collaborative de novo genome ...
... even in the cloudiest conditions, while the lush interiors ... canopy. The ability of trees to adapt to light ... photosynthesis in poor light, has been explored by Czech ... Functional Ecology . The research centers around the ...
... In a review study, researchers from Tufts University ... use of antibiotics in food animals and fish farming ... the preponderance of evidence argues for stricter regulation of ... resistance, notes that a guiding tenet of public health, ...
Cached Biology News:BGI announces collaborative research agreements with Oregon State University 2Trees adapt to poor levels of sunlight to effectively process carbon, study shows 2Evidence supports ban on growth promotion use of antibiotics in farming 2Evidence supports ban on growth promotion use of antibiotics in farming 3Evidence supports ban on growth promotion use of antibiotics in farming 4
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for BrdU in cells and tissues...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: